Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents

被引:22
作者
Barletta, E
Gorini, G
Vineis, P
Miligi, L
Davico, L
Mugnai, G
Ciolli, S
Leoni, F
Bertini, M
Matullo, G
Costantini, AS
机构
[1] Univ Florence, Dept Expt Pathol & Oncol, Florence, Italy
[2] Univ Turin, ISI Fdn, Turin, Italy
[3] Univ Turin, Dept Mol Genet & Biochem, Turin, Italy
[4] AO San Giovanni Battista, Dept Haematol, Turin, Italy
[5] Univ Turin, AO San Giovanni Battista, Dept Biomed Sci & Human Oncol, Turin, Italy
关键词
D O I
10.1093/carcin/bgh057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations of the N- and K-ras genes occur in similar to15-30% of acute myeloid leukaemia patients. The role of the oncogenic ras in leukaemogenesis remains unclear. Few studies have revealed that mutations in the ras oncogene family are more probably found in acute myeloid leukaemia patients with previous exposure to toxic agents. A case-case study was conducted in the areas of Florence and Turin, Italy, to investigate whether the presence of N- and K-ras mutations in acute myeloid leukaemia patients was related to a higher frequency of exposure to chemicals. During a 3-year period, 111 acute myeloid leukaemia patients were enrolled. All the patients were interviewed using a semi-structured questionnaire collecting data on residential history, occupation, personal habits and pathological history. The presence of N- and K-ras mutations was analysed by amplification and synthetic oligonucleotide probes and by the so-called polymerase chain reaction amplification for specific alleles technique. A total of 34 (30.6%) patients were found to harbour ras mutations in N-ras and/or K-ras. Fourteen patients (12.6%) had a single ras mutation and 20 patients (18%) had two ras mutations. A positive association between a priori at risk jobs and ras mutations was found, based on nine exposed cases; the odds ratio, adjusted by age, sex and previous X-ray and/or chemotherapy was 2.8 (95% confidence intervals: 0.9-9.0). When considering only subjects with two ras mutations the odds ratio was 4.8 (95% confidence intervals: 1.2-18.8). The odds ratio for a previous X-ray and/or chemotherapy was 16.2 (95% confidence intervals: 1.8-755.9); when only subjects with two ras mutations were considered, the odds ratio was 26.1 (95% confidence intervals: 2.5-1248.9). In conclusion, our data suggest that ras oncogene mutations might identify a group of leukaemia in people with previous X-ray/chemotherapy or with exposure to chemical agents in the work environment.
引用
收藏
页码:749 / 755
页数:7
相关论文
共 40 条
[1]   Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer [J].
Alguacil, J ;
Porta, M ;
Malats, N ;
Kauppinen, T ;
Kogevinas, M ;
Benavides, FG ;
Partanen, T ;
Carrato, A .
CARCINOGENESIS, 2002, 23 (01) :101-106
[2]  
[Anonymous], 2001, STAT STAT SOFTW REL
[3]   RAS ONCOGENES - THEIR ROLE IN NEOPLASIA [J].
BARBACID, M .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (03) :225-235
[4]  
BASHEY A, 1992, BLOOD, V79, P981
[5]   p14ARF links the tumour suppressors RB and p53 [J].
Bates, S ;
Phillips, AC ;
Clark, PA ;
Stott, F ;
Peters, G ;
Ludwig, RL ;
Vousden, KH .
NATURE, 1998, 395 (6698) :124-125
[6]   Functional interactions and signaling properties of mammalian DNA mismatch repair proteins [J].
Bellacosa, A .
CELL DEATH AND DIFFERENTIATION, 2001, 8 (11) :1076-1092
[7]  
BOS JL, 1989, CANCER RES, V49, P4682
[8]  
Byrne JL, 1998, BRIT J HAEMATOL, V100, P256
[9]  
CARTER G, 1990, ONCOGENE, V5, P411
[10]   Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome [J].
Casorelli, I ;
Offman, J ;
Mele, L ;
Pagano, L ;
Sica, S ;
D'Errico, M ;
Giannini, G ;
Leone, G ;
Bignami, M ;
Karran, P .
DNA REPAIR, 2003, 2 (05) :547-559